CRON

Cronos Group Inc. (CRON:CA) Analyst/Investor Day Transcript

Cronos Group NASDAQ: CRON used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation.

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.

Cronos Group Inc. is upgraded to a Buy, driven by a best-in-class balance sheet and improved profitability. CRON boasts $827 million in cash, no debt, and strong international expansion, with adjusted gross margins reaching 46%. Profitability is supported by disciplined cost management and positive GAAP operating profit, distinguishing CRON from Canadian peers.

Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026 Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch.

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.

Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.